Description

ATS Corporation: Energy, Life Sciences, & Data—The Multi-Vector Growth Story Investors Are Underpricing!

ATS Corporation has delivered its second-quarter financial results for fiscal year 2026, reflecting a significant improvement in organic growth and adjusted earnings margins, in line with expectations. The company’s order bookings were reported at $734 million, a slight 1.1% decrease year over year due to a high comparison from prior large enterprise bookings in the Life Sciences segment. Despite this, sequential growth was noted due to robust performance across diversified end markets. Revenues for the quarter stood at $729 million, marking an 18.9% increase from the previous year driven mainly by organic growth, foreign exchange benefits, and contributions from recent acquisitions. Several focal points emerge from the results. Life Sciences remains a key driver for ATS, with backlog figures reaching $1.1 billion owing to sustained demand across various submarkets, including radiopharma and auto-injectors, among others.